KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Non-Current Debt: 2022-2024

Historic Non-Current Debt for Adaptive Biotechnologies (ADPT) over the last 3 years, with Dec 2024 value amounting to $132.4 million.

  • Adaptive Biotechnologies' Non-Current Debt fell 2.48% to $129.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.4 million, marking a year-over-year decrease of 2.48%. This contributed to the annual value of $132.4 million for FY2024, which is 1.34% up from last year.
  • According to the latest figures from FY2024, Adaptive Biotechnologies' Non-Current Debt is $132.4 million, which was up 1.34% from $130.7 million recorded in FY2023.
  • Adaptive Biotechnologies' 5-year Non-Current Debt high stood at $132.4 million for FY2024, and its period low was $125.4 million during FY2022.
  • Its 3-year average for Non-Current Debt is $129.5 million, with a median of $130.7 million in 2023.
  • Data for Adaptive Biotechnologies' Non-Current Debt shows a peak YoY rose of 4.23% (in 2023) over the last 5 years.
  • Over the past 3 years, Adaptive Biotechnologies' Non-Current Debt (Yearly) stood at $125.4 million in 2022, then grew by 4.23% to $130.7 million in 2023, then rose by 1.34% to $132.4 million in 2024.